point around 300 ng/dL. Supplementing men who may have serum levels greater than these cutoffs is potentially risky and of unclear clinical benefit.
Unfortunately, providers who are not knowledgeable about established cut-offs are likely less prone to read literature such as this paper. It behooves medical practices and regulatory agencies to ensure that their practitioners adhere to the best available evidence-based guidelines; at a minimum, this should mean pretreatment assessment of serum testosterone levels and follow-up to ensure appropriate supplementation is achieved.
Alan W. Shindel, MD, MAS
Hypogonadal symptoms are associated with different serum testosterone thresholds in middle-aged and elderly men. R Ramasamy, N Wilken, JM Scovell, JR Kovac, LI Lipshultz. Urology 2014;84:1378-82. Editorial Comment: There exists substantial controversy about serum testosterone levels; what constitutes "low T"? Reference ranges vary widely between labs, and assays themselves are prone to marked variation. Aside from issues with testosterone itself, there is a growing body of evidence to suggest that variations in the androgen receptor may modulate the potency of serum testosterone in vivo. When coupled with the generally vague nature of "low T" symptoms, proper patient selection can be challenging. Most organizations to date have favored a cutoff range around 300 ng/dL serum testosterone for "low testosterone." This interesting study suggests that a "one-size-fits-all" approach to serum testosterone testing may not be appropriate and that some men with higher testosterone levels may still have significant symptom burden. Interestingly, decreased libido, one of the more common low T complaints, became increasingly prevalent in men with serum levels less than 375 ng/dL, well above the more standard cut off of 300 ng/dL. Progressively lower levels (still over 300 ng/dL) corresponded with increasing prevalence of the physical symptoms of low testosterone (decreased ability with sports, loss of strength, etc). Wu et al. [1] reported that certain symptoms of testosterone deficiency become more prevalent with progressively lower serum levels, so this paper adds to this prior work.
The study is limited in its use of the nonspecific ADAM questionnaire. It does however give credence to the notion that clinicians should use their own judgment and carefully counsel patients who have symptoms of low T and borderline levels. Supplementation may be of benefit in such men, but careful discussion and informed consent of the patient are essential.
Alan 
Female Clinical Science
Mechanism of action of Fibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. SM Stahl. CNS Spectr 2015;20:1-6. Editorial Comment: For decades, the field of sexual medicine has been bombarded by scientific breakthroughs when it comes to pathophysiological understanding of the endocrinological aspects of male sexual function and dysfunction. We have noticed a significant lag in the understanding when it pertains to female sexual health and wellness. This article takes a deep dive into the female brain and hormonal regulation of female sexual interest and desire. We now can glean from the presented evidences that sexual desire is regulated not only by sex hormones (e.g., testosterone, estrogen, and progesterone) but also by brain neurotransmitters. Principle among these are dopamine and norepinephrine, which work in concert to enhance sexual interest and desire. Serotonin levels are also critical as they appear to act directly to inhibit sexual interest and desire. Brain circuitry involved in connecting the prefrontal cortex with emotional/limbic pleasure centers may be integrally involved in mediating personal and sexual motivation, interest, and desire. One may consider that dysregulation in these circuits will result in abnormal and/or deficient information processing; this may result in disorders of sexual interest and desire. Flibanserin, a novel medication which has recently been resubmitted to the Food and Drug administration for approval for female HSDD, is a multifunctional serotonergic agent with both 1A agonist and a serotonin 2A antagonist properties.
Flibanserin's most likely mechanism of action is by boosting pathways involved in the release of dopamine and norepinephrine while concurrently reducing serotonin release. By these mechanisms, the drug facilitates an improvement in sexual functioning with associated decrease in sex-related distress. Flibanserin is a novel multifunctional serotonin agonist and antagonist that has demonstrated improved sexual functioning in premenopausal women who suffer from reduced sexual interest and desire. This review is a must read! Michael Krychman, MD Editorial Comment: Obesity is running rampant both globally and within the United States. We have long recognized some of the medical and physical ramifications from increased body mass index (BMI) and have now labeled obesity a medical illness which warrants intervention to decrease morbidity and mortality. Obesity is considered grade I when the BMI is less than 30 kg/ m 2 , grade II when the BMI is equal to or greater than 35 kg/m 2 , and grade III when the BMI is equal to or greater than 40 kg/m 2 . Sexual problems and dysfunction have long been associated with changes in weight, and it has been demonstrated that severe obesity is a contributing facet to poor overall sexual functioning.
Many patients are now opting for aggressive surgical treatment for obesity. While treatment is effective in managing weight issues, there are limited data on sexual function outcomes in these patients. Increased attention to postoperative sexuality issues is an important component of overall quality of life assessment in patients who have undergone bariatric surgery.
Obese people may experience a variety of medical and psychological ramifications from their increased weight including (but not limited to) discrimination, body image disorders, anxiety, depression, low self-esteem, isolation, hypertension, metabolic syndrome, and diabetes. Morbid obesity may directly impact sexuality by fatigue, decreased physical stamina/mobility, lower sexual self-esteem, and/or guilt and shame. There are positive outcomes of physical and emotional domains after the surgical treatment of obesity, favoring the improved quality of life, including sexuality.
This small yet significant qualitative/ quantitative research study followed a nonrandom sample of 30 patients who had undergone FobiCapella Roux-Y gastric bypass. Data collection occurred through individual interviews and questionnaires between May and June 2011. The mean age of the patients was 44 ± 12 years. The majority of participants (24, 80%) were female. Seventyseven percent were married. Almost all (96%) had hypertension, whereas only and eight (33%) had diabetes. The average weight loss postoperatively was 44 ± 13.8 kg for women and 47 ± 16.3 kg for men. Mean weight loss as a percentage was 36% for both genders.
Postoperatively, 63% of participants reported that sexual frequency was changed: 16 (53%) reported increased sex frequency, one (3%) reported a decrease in frequency, one (3%) completely stopped having intercourse, and one (3%) did not report on sex frequency; 37% of individuals reported no change in intercourse frequency.
Data such as these support the notion that sexual health improves with management of obesity. As the population ages, and as obesity and morbid obesity become more prevalent, it is critical for us to examine our own preconceived notions on obesity and recognize that bariatric surgery may provide a new start toward improved sexual function, desire, and sexual capacity.
Michael Krychman, MD [1] . Functional MRI (fMRI) has also been used in the clinical setting to reveal central sexual excitation. FMRI is able to detect even slight changes in blood flow; this property has enabled the discovery that with normative sexual response, there is deactivation of the frontal lobe and activation of the instinctual limbic system of the midbrain.
MRI has also been instrumental in assessment and documentation of the complete clitoral complex. Careful imaging studies have demonstrated the distinct nature of the clitoral glans and the paired clitoral corpora, crura, and bulbs. Important discoveries have included documentation of the average clitoral sizes and its associated structures as well as the distances between the clitoral complex and other pelvic structures.
Interestingly, MRI-based anatomical measurements have been associated with variation in female sexual function. For instance, increased distance between the clitoral complex and the vaginal lumen correlates with poorer sexual function. Genital and subjective arousal are only weakly correlated in women; however, physiological engorgement is beneficial for many aspects of female sexual arousal. Indeed, it is the opinion of many sexual medicine specialists that arousal disorder is likely to due to a combination of inadequate desire, deficient central activation, and poor peripheral vascular engorgement.
Unfortunately, MRI is expensive in the US (less so in other countries), lacks portability, is both time-consuming, and may be difficult in patients who are claustrophobic or sensitive to noise. Furthermore, MRI is contraindicated in patients with metal implants. Despite these limitations, MRI technology is an increasingly vital adjunct in clinical research for female sexuality. It is conceivable that in the near future, MRI may have direct clini-cal applications in the diagnosis and management of female sexual concerns.
Michael Krychman, MD In this study, a nonclinical/noncriminal sample of 1,580 female participants were recruited through kink community events and online forums. Participants were invited to fill out an online questionnaire asking about the types of kink activities these women have participated in and the type of participation (doing to, having done to, observing). The questionnaire asked about 126 sensual, erotic, and sexual behaviors among these women including 62 BDSM-related behaviors, 10 role-play scenarios, five forms of exhibitionistic behaviors, eight forms of erotica, five broad categories of fetishistic behaviors, 24 overt sexual activities, and 12 miscellaneous erotic activities.
The researchers determined that women in the kink community willingly engage in a much wider variety of erotic activities than has previously been documented in the literature. Of interest, 85% percent of the sample indicated using bondage toys, 82% indicated that they have observed some type of erotica, and 56% indicated engaging in some type of exhibitionistic activity (e.g., showing bare breasts, engaging in public sex, posing or sharing images, etc.) for their own sensual or erotic pleasure.
The results of this study provide educators, counselors, therapists, and medical professionals a much better understanding of the depth and breadth of activities women willingly engage in the kink community. It also adds to the literature by providing data on kink behaviors in women from a nonpathologizing perspective.
Rose Hartzell-Cushanick, PhD, EdS, CHES, LMFT
Women's motivations to have sex in casual and committed relationships with male and female partner. HL Armstrong, ED Reissing. Arch Sex Behav 2015;44:921-34. Editorial Comment: Women are motivated to engage in sexual activity for a variety of reasons, and these motivations may change from one context to another. A better understanding of how these sexual motives work in women can help sex therapists, educators, and physicians more effectively work with women with low sexual desire or those engaging in risky sexual behavior.
In this study, the authors explored how relationship type, sexual attraction, and the gender of one's partner interact and affect sexual motivation. Women were recruited at a large university through online advertising and by word-of-mouth. A total of 510 women completed the YSEX? Questionnaire. This survey posed questions about motivations for sex in the past and/or what would motivate them to engage in sexual activity in the future. Examples of potential enticements to sex included wanting to achieve an orgasm, being "horny," and/or the potential partner's physical appearance "turning them on."
The authors report that the type of relationship (casual vs. committed) affected the women's reported motivation for sex. For causal sex, physical reasons were most frequently endorsed as motivations, whereas for committed relationships, women more frequently motivated by emotional needs/ desires. These results were consistent regardless of the gender of their partner (i.e., if their potential partner was another woman or a man).
This study is an important contribution to the literature and can benefit sexual health practitioners/therapists working with women by providing them with more insight into women's sexual motivations (e.g., in working with women reporting symptoms of low sexual desire). In addition, the similarity in sexual motivation for women, regardless of sexual orientation or gender of partner, is also noteworthy. Vulvodynia adversely impacts women's sexual health, psychological well-being, and quality of life. Unfortunately, most studies in the area, both biomedical and psychosocial, are characterized by relatively small clinical samples. This significant limitation introduces a selection bias associated with clinically referred participants, who typically show higher levels of symptomatology. The field is in dire need of large-scale community-based studies; such data will inform scientists and health care providers about population prevalence, helpseeking behaviors and attitudes, and risk factors for the development of this neglected women's sexual health issue.
One such important study was recently published [2] . Bernard Harlow and his team gathered epidemiologic data from 5,440 premenopausal women from three ethnically diverse neighborhoods and two west suburban communities of the Boston metropolitan area (BMA) between 2001 and 2005, and 13,681 from all geographic locations within the Minneapolis/St Paul metropolitan area (MSP) between 2010 and 2012. Participants completed the self-report measures concerning their history of vulvar pain that interfered with vaginal intercourse and that lasted more than 3 months. Participants from BMA were systematically sampled from census-based directories, and those from MSP stemmed from an administrative database of women who were seen for any reason at one of several outpatient community clinics within that defined geographic region.
Although boasting large representative samples, community-based studies have the inevitable disadvantage of needing to forego more in-depth assessment of study participants. In the case of vulvodynia, this may mean that women cannot take part in a gynecological examination to confirm their diagnosis. To circumvent this caveat, Harlow and colleagues first developed a vulvar pain questionnaire which has shown 83% sensitivity and 94% specificity for meeting a medical diagnosis of vulvodynia, based on the cotton swab test and other elements of clinical examination to rule out potential known causes of vulvar pain [3] .
To determine age-specific cumulative incidence in the present study, the authors defined vulvodynia as pain on contact in the last 6 months that limited or prevented intercourse. Results indicate that for both samples, the rate of first onset of vulvodynia was highest prior to the age of 25 years, decreased during the late 20s and early 30s, and then increased in participants' late 30s. These results are similar to what is often observed clinically when speaking to women with sexual pain. Interestingly, women of Hispanic ethnicity were at an increased risk of developing vulvodynia.
Overall, 7-8% of women in this study reported symptoms consistent with vulvodynia by age 40. Among women with vulvodynia, between 30% and 48% never sought treatment; unfortunately, over 50% of those who sought care never received a diagnosis. Those with primary vulvodynia (i.e., pain on genital contact/intercourse since the first vaginal intercourse attempt) were more likely to have sought treatment compared with women with secondary vulvodynia (i.e., pain after a period of pain-free intercourse).
Two significant conclusions can be drawn from this study. First, vulvodynia is a highly prevalent condition that is often neglected by many health care professionals. Potential explanations for failure to address the issue in practice include ignorance, lack of training, discomfort discussing sexuality, and feelings of helplessness in the face of a persistent yet private pain condition that is challenging to treat. Second, almost half of women with vulvodynia do not seek treatment; even those women who do seek treatment are frequently frustrated by failure to receive a diagnosis. One may glean from this that existing studies on vulvodynia based on clinical samples represent a self-selected, limited, and biased group of women. Given that the best available data may be based on a biased population, it may be inferred that accurate knowledge on vulvodynia is less than accurate, even among sexual medicine specialists.
Sophie Bergeron, PhD
